We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Dean Seal Mesoblast said regulators have granted their rare pediatric disease designation to its cell therapy Revascor for children with hypoplastic left heart syndrome. The Australian...
By Colin Kellaher American depositary shares of Mesoblast plummeted more than 65% in premarket trading Friday after the biopharmaceutical company's latest setback in its bid to win U.S. Food...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.23 | 68.6567164179 | 0.335 | 0.59 | 0.325 | 14304257 | 0.45033107 | DE |
4 | 0.27 | 91.5254237288 | 0.295 | 0.59 | 0.29 | 9404999 | 0.38584594 | DE |
12 | 0.26 | 85.2459016393 | 0.305 | 0.59 | 0.255 | 4956336 | 0.34937271 | DE |
26 | 0.205 | 56.9444444444 | 0.36 | 0.59 | 0.255 | 4045460 | 0.34545252 | DE |
52 | -0.355 | -38.5869565217 | 0.92 | 1.425 | 0.255 | 4215303 | 0.50203532 | DE |
156 | -1.725 | -75.327510917 | 2.29 | 2.34 | 0.255 | 2674228 | 0.95190984 | DE |
260 | -0.86 | -60.350877193 | 1.425 | 5.7 | 0.255 | 3579647 | 2.19103289 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions